These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10761715)

  • 1. Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride.
    Hori K; Saito S; Takahashi H; Sato H; Maeda H; Sato Y
    Jpn J Cancer Res; 2000 Feb; 91(2):261-9. PubMed ID: 10761715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700.
    Hori K; Saito S; Nihei Y; Suzuki M; Sato Y
    Jpn J Cancer Res; 1999 Sep; 90(9):1026-38. PubMed ID: 10551334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.
    Zheng Y; Shirato I; Maeda A; Kobayashi N; Liao J; Shou I; Fukui M; Tomino Y
    J Nephrol; 2002; 15(1):36-41. PubMed ID: 11936424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the angiotensin converting enzyme inhibitor temocapril on insulin sensitivity and its effects on renal sodium handling and the pressor system in essential hypertensive patients.
    Miyazaki Y; Murakami H; Hirata A; Fukuoka M; Masuda A; Ura N; Shimamoto K
    Am J Hypertens; 1998 Aug; 11(8 Pt 1):962-70. PubMed ID: 9715789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats.
    Higashiura K; Ura N; Takada T; Li Y; Torii T; Togashi N; Takada M; Takizawa H; Shimamoto K
    Am J Hypertens; 2000 Mar; 13(3):290-7. PubMed ID: 10777034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological and clinical studies with temocapril, an angiotensin converting enzyme inhibitor that is excreted in the bile.
    Yasunari K; Maeda K; Nakamura M; Watanabe T; Yoshikawa J; Asada A
    Cardiovasc Drug Rev; 2004; 22(3):189-98. PubMed ID: 15492767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing time-dependent effect of temocapril on the mortality of stroke-prone spontaneously hypertensive rats.
    Nozawa M; Sugimoto K; Ohmori M; Ando H; Fujimura A
    J Pharmacol Exp Ther; 2006 Jan; 316(1):176-81. PubMed ID: 16174798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Temocapril treatment upregulated cardiomyocyte thioredoxin expression and improved autoimmune myocarditis].
    Yuan ZY; Liu Y; Kishimoto C; Shioji K; Yodoi J; Liu ZQ
    Zhonghua Nei Ke Za Zhi; 2003 May; 42(5):309-12. PubMed ID: 12882710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of temocapril on cultured ventral spinal cord neurons.
    Iwasaki Y; Ichikawa Y; Igarash O; Ikeda K; Kinoshita M
    Neurochem Res; 2003 May; 28(5):711-4. PubMed ID: 12716021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelium-derived hydrogen peroxide accounts for the enhancing effect of an angiotensin-converting enzyme inhibitor on endothelium-derived hyperpolarizing factor-mediated responses in mice.
    Fujiki T; Shimokawa H; Morikawa K; Kubota H; Hatanaka M; Talukder MA; Matoba T; Takeshita A; Sunagawa K
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):766-71. PubMed ID: 15705930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect.
    Hori K; Saito S; Sato Y; Kubota K
    Med Sci Monit; 2001; 7(1):26-33. PubMed ID: 11208488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist.
    Kawata T; Daimon M; Hasegawa R; Teramoto K; Toyoda T; Sekine T; Yamamoto K; Uchida D; Himi T; Yoshida K; Komuro I
    Am Heart J; 2006 Apr; 151(4):798.e9-15. PubMed ID: 16569537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temocapril, an Angiotensin converting enzyme inhibitor, ameliorates age-related increase in carotid arterial stiffness in normotensive subjects.
    Hayashi K; Miyagawa K; Sato K; Ueda R; Dohi Y
    Cardiology; 2006; 106(3):190-4. PubMed ID: 16675905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circadian variation of tumor blood flow in rat subcutaneous tumors and its alteration by angiotensin II-induced hypertension.
    Hori K; Suzuki M; Tanda S; Saito S; Shinozaki M; Zhang QH
    Cancer Res; 1992 Feb; 52(4):912-6. PubMed ID: 1737354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temocapril treatment ameliorates autoimmune myocarditis associated with enhanced cardiomyocyte thioredoxin expression.
    Yuan Z; Kishimoto C; Shioji K; Nakamura H; Yodoi J; Sasayama S
    Mol Cell Biochem; 2003 Jun; 248(1-2):185-92. PubMed ID: 12870672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of temocapril and olmesartan on myocardial sympathetic nervous activity and fatty acid metabolism in rats with chronic beta-adrenergic stimulation.
    Ido A; Hasebe N; Takeuchi T; Kikuchi K
    J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S133-7. PubMed ID: 12688410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin I-converting enzyme inhibitor improves reactive hyperemia in elderly hypertensives with arteriosclerosis obliterans.
    Okuro M; Morimoto S; Takahashi T; Okaishi K; Nakahashi T; Murai H; Iwai K; Kanda T; Matsumoto M
    Hypertens Res; 2006 Sep; 29(9):655-63. PubMed ID: 17249520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluctuations in tumor blood flow under normotension and the effect of angiotensin II-induced hypertension.
    Hori K; Suzuki M; Tanda S; Saito S; Shinozaki M; Zhang QH
    Jpn J Cancer Res; 1991 Nov; 82(11):1309-16. PubMed ID: 1752787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temocapril prevents motor neuron damage and upregulation of cyclooxygenase-II in glutamate-induced neurotoxicity.
    Iwasaki Y; Ichikawa Y; Igarashi O; Ikeda K; Konno S; Aoyagi J; Kinoshita M
    Neurol Res; 2003 Apr; 25(3):301-4. PubMed ID: 12739242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study.
    Katayama S; Kawamori R; Iwamoto Y; Saito I; Kuramoto K;
    Hypertens Res; 2008 Aug; 31(8):1499-508. PubMed ID: 18971523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.